Inspections, Compliance, Enforcement, and Criminal Investigations
Advanced Medical Optics Uppsala Ab Close out Letter 12/20/11
Department of Health and Human Services
|Public Health Service|
Food and Drug Administration
|10903 New Hampshire Avenue|
Silver Spring, MD 20993
DEC 20 2011
Mr. Billy Call
Managing Plant Director
Abbott Medical Optics Uppsala Ab
Rapsgatan 7, Box 6406
Uppsala 75136, Sweden
Dear Mr. Call:
The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter #68104, dated September 18, 2009. Based on our evaluation, it appears that you have addressed the violation contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Steven D. Silverman
Office of Compliance
Center for Devices and
Ms. Sandra Selvaggi
Senior Director, Quality & Compliance
Abbott Medical Optics, Inc.
1700 East Saint Andrew Place
Santa Ana, California 92705-4933